BresaGen signs two new contracts
Tuesday, 02 August, 2005
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
The first is with Irish based Opsona Therapeutics, which will use BresaGen to progress process development of its pre-clinical immunomodulator, OPN-201. The second contract is with US firm Pepgen Corporation, which first partnered with BresaGen in 2004, to develop a process for Pepgen to produce a novel interferon alpha analog, Neoferon.
Under the contract, BresaGen will further develop the E. coli-based process and produce GLP recombinant protein.
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Genetics shape our personality and life outcomes more than we thought
Scientists have identified >1200 genetic variants associated with personality traits,...
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
